Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).

BMC Cancer · 2016 · PMC5073820 · PMID 27769210

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

did not reach statistical significanceP = 0.053so close (0.05 < p ≤ 0.1)

In patients treated to AEs, PFS was numerically longer for patients treated with nab -P + Gem compared with those who received Gem alone, although this difference did not reach statistical significance (median, 5.5 vs 5.0 months; HR, 0.63; P = 0.053).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.